Skip to main content

Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery

The European Journal of Health Economics volume 8, pages 313–323 (2007)Cite this article

Abstract

A model was developed to estimate costs and clinical effectiveness of fondaparinux compared with enoxaparin after hip fracture surgery in Sweden. Outcomes and costs of venous thromboembolism (VTE)-related care from a health care perspective were incorporated, with symptomatic deep-vein thrombosis and pulmonary embolism, recurrent VTE, post-thrombotic syndrome, major haemorrhage and all-cause death being included. Event probabilities were derived from fondaparinux clinical trial data and published data. VTE-related resource use and associated costs as well as costs of prophylaxis were based on local Swedish data. Extended prophylaxis with fondaparinux could avoid an additional 28 symptomatic VTE per 1,000 patients compared with extended prophylaxis with enoxaparin in hip fracture surgery patients. Although the prophylaxis costs were higher in the fondaparinux group, these were offset by the lower costs associated with treating fewer VTE, which thus indicates that extended fondaparinux prophylaxis is the dominant alternative when compared with enoxaparin in hip fracture surgery.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Blodpropp-förebyggande, diagnostik o behandling av venös tromboembolism (in Swedish): The Swedish Council on Technology Assessment in Health Care (SBU), Linköping (2002)

  2. Saunders, M.E., Grant, R.E.: Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery. J. Natl. Med. Assoc. 90(11), 677–680 (1998)

    Google Scholar 

  3. Menzin, J., Colditz, G.A., Regan, M.M., Richner, R.E., Oster, G.: Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch. Intern. Med. 155(7), 757–764 (1995)

    Article  Google Scholar 

  4. Lundkvist, J., Bergqvist, D., Jönsson, B.: Cost effectiveness of fondaparinux compared to enoxaparin as venous thromboembolism prophylaxis in Sweden. Eur. J. Health Econ. 4(4), 254–262 (2003)

    Article  Google Scholar 

  5. Balen, R.M., Marra, C.A., Zed, P.J., Cohen, M., Frighetto, L.: Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective. Pharmacoeconomics 16(5 Pt 2), 533–542 (1999)

    Article  Google Scholar 

  6. Bergqvist, D.: Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes. Pharmacoeconomics 20(4), 225–243 (2002)

    Article  Google Scholar 

  7. Geerts, W.H., Heit, J.A., Clagett, G.P., Pineo, G.F., Colwell, C.W., et al.: Prevention of venous thromboembolism. Chest 119(1 Suppl), 132S–175S (2001)

    Article  Google Scholar 

  8. Data on file, Sanofi-Synthelabo (2003)

  9. Eikelboom, J.W., Quinlan, D.J., Douketis, J.D.: Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358(9275), 9–15 (2001)

    Article  Google Scholar 

  10. Bergqvist, D., Jonsson, B.: Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement. Haemostasis 30 Suppl 2130–2135; discussion 128–129 (2000)

    Google Scholar 

  11. Hull, R.D., Pineo, G.F., Stein, P.D., Mah, A.F., MacIsaac, S.M., et al.: Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann. Intern. Med. 135(10), 858–869 (2001)

    Google Scholar 

  12. Davies, L., Richardson, G., Cohen, A.: Economic evaluation of enoxaparin as postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery. Value Health 3(6), 397–406 (2000)

    Article  Google Scholar 

  13. Detournay, B., Planes, A., Vochelle, N., Fagnani, F.: Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics 13(1 Pt 1), 81–89 (1998)

    Article  Google Scholar 

  14. Eriksson, B.I., Lassen, M.R.: Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch. Intern. Med. 163(11), 1337–42 (2003)

    Article  Google Scholar 

  15. Gordois, A.: The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J. Thromb. Haemost. 1(10), 2167–2174 (2003)

    Article  Google Scholar 

  16. Sullivan, S.: Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxi against venous thromboembolsim in patients undergoing major orthopedic surgery. Blood 100(11), 871 (2002)

    Google Scholar 

  17. Lassen, M.R., Borris, L.C., Anderson, B.S., Jensen, H.P., Skejo Bro, H.P., et al.: Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty–the Danish Prolonged Prophylaxis (DaPP) Study. Thromb. Res. 89(6), 281–287 (1998)

    Article  Google Scholar 

  18. Turpie, A.G., Bauer, K.A., Eriksson, B.I., Lassen, M.R.: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359(9319), 1721–1726 (2002)

    Article  Google Scholar 

  19. Eriksson, B.I., Bauer, K.A., Lassen, M.R., Turpie, A.G.: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med. 345(18), 1298–1304 (2001)

    Article  Google Scholar 

  20. White, R.H., Romano, P.S., Zhou, H., Rodrigo, J., Bargar, W.: Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch. Intern. Med. 158(14), 1525–1531 (1998)

    Article  Google Scholar 

  21. Devlin, J.W., Petitta, A., Shepard, A.D., Obeid, F.N.: Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma. Pharmacotherapy 18(6), 1335–1342 (1998)

    Google Scholar 

  22. Drummond, M., Aristides, M., Davies, L., Forbes, C.: Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br. J. Surg. 81(12), 1742–1746 (1994)

    Article  Google Scholar 

  23. Hillson, S.D., Rich, E.C.: Two strategies for prophylaxis of fatal postoperative pulmonary embolism. Cost-effectiveness analysis. Int. J. Technol. Assess Health Care 6(3), 470–479 (1990)

    Article  Google Scholar 

  24. Hawkins, D.W., Langley, P.C., Krueger, K.P.: Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am. J. Health Syst. Pharm. 54(10), 1185–1190 (1997)

    Google Scholar 

  25. Levin, L.A., Horst, M., Bergqvist, D.: Economic evaluation of desirudin vs heparin in deep vein thrombosis prevention after hip replacement surgery. Pharmacoeconomics 13(1 Pt 2), 111–118 (1998)

    Article  Google Scholar 

  26. Levin, L.A., Bergqvist, D.: Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery. Pharmacoeconomics 19(5 Pt 2), 589–597 (2001)

    Article  Google Scholar 

  27. Lloyd, A: Economic evaluation of the use of enoxaparin for thomboprophylaxis in acutely ill medical patients. J. Drug Assess. 4145–159

  28. Lloyd, A., Aitken, J.A., Hoffmeyer, U.K., Kelso, E.J., Wakerly, E.C., et al.: Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy. Pharmacoeconomics 12(4), 475–485 (1997)

    Google Scholar 

  29. Nicolaides, A., Bosanquet, N.: Cost-effectiveness of desirudin in the prevention of the thromboemebolism complications of surgery. J. Drug Assess. 2353–2364 (1999)

  30. O’Brien, B.J., Anderson, D.R., Goeree, R.: Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Cmaj 150(7), 1083–1090 (1994)

    Google Scholar 

  31. Oster, G., Tuden, R.L., Colditz, G.A.: A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA 257(2), 203–8 (1987)

    Article  Google Scholar 

  32. Oster, G., Tuden, R.L., Colditz, G.A.: Prevention of venous thromboembolism after general surgery. Cost-effectiveness analysis of alternative approaches to prophylaxis. Am. J. Med. 82(5), 889–99 (1987)

    Article  Google Scholar 

  33. Pechevis, M.: Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely III medical patients. Value Health 3(6), 389–396 (2000)

    Article  Google Scholar 

  34. Szucs, T.D., Schramm, W.: The cost-effectiveness of low-molecular-weight heparin vs unfractionated heparin in general and orthopaedic surgery: an analysis for the German healthcare system. Pharmacol. Res. 40(1), 83–89 (1999)

    Article  Google Scholar 

  35. Prandoni, P., Lensing, A.W., Cogo, A., Cuppini, S., Villalta, S., et al.: The long-term clinical course of acute deep venous thrombosis. Ann. Intern. Med. 125(1), 1–7 (1996)

    Google Scholar 

  36. Hull, R., Delmore, T., Carter, C., Hirsh, J., Genton, E., et al.: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N. Engl. J. Med. 306(4), 189–194 (1982)

    Article  Google Scholar 

  37. Hull, R., Hirsh, J., Jay, R., Carter, C., England, C., et al.: Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 307(27), 1676–1681 (1982)

    Article  Google Scholar 

  38. Lagerstedt, C.I., Olsson, C.G., Fagher, B.O., Oqvist, B.W., Albrechtsson, U.: Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 2(8454), 515–518 (1985)

    Article  Google Scholar 

  39. Pini, M., Aiello, S., Manotti, C., Pattacini, C., Quintavalla, R., et al.: Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb. Haemost. 72(2), 191–197 (1994)

    Google Scholar 

  40. Schulman, S., Rhedin, A.S., Lindmarker, P., Carlsson, A., Larfars, G., et al.: A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N. Engl. J. Med. 332(25), 1661–1665 (1995)

    Article  Google Scholar 

  41. Das, S.K., Cohen, A.T., Edmondson, R.A., Melissari, E., Kakkar, V.V.: Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J. Surg. 20(5), 521–526; discussion 526–527 (1996)

    Google Scholar 

  42. Ginsberg, J.S., Turkstra, F., Buller, H.R., MacKinnon, B., Magier, D., et al.: Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch. Intern. Med. 160(5), 669–672 (2000)

    Article  Google Scholar 

  43. Siragusa, S., Beltrametti, C., Barone, M., Piovella, F.: Clinical course and incidence of post-thrombophlebitic syndrome after profound asymptomatic deep vein thrombosis. Results of a transverse epidemiologic study. Minerva Cardioangiol. 45(3), 57–66 (1997)

    Google Scholar 

  44. Life tables. Statistic Sweden, Stockholm (2003)

  45. Johnell, O., Kanis, J.A., Oden, A., Sernbo, I., Redlund-Johnell, I., et al.: Mortality after osteoporotic fractures. Osteoporos. Int. 15(1), 38–42 (2004)

    Article  Google Scholar 

  46. Braithwaite, R.S., Col, N.F., Wong, J.B.: Estimating hip fracture morbidity, mortality and costs. J. Am. Geriatr. Soc. 51(3), 364–370 (2003)

    Article  Google Scholar 

  47. Kanis, J.A., Oden, A., Johnell, O., De Laet, C., Jonsson, B., et al.: The components of excess mortality after hip fracture. Bone 32(5), 468–473 (2003)

    Article  Google Scholar 

  48. Manning, W.G.: The logged dependent variable, heteroscedasticity, and the retransformation problem. J. Health Econ. 17(3), 283–295 (1998)

    Article  Google Scholar 

  49. Manning, W.G., Mullahy, J.: Estimating log models: to transform or not to transform? J. Health Econ. 20(4), 461–494 (2001)

    Article  Google Scholar 

  50. LINFO FASS Läkemedel i Sverige (Swedish drug prices). Läkemedelsinformation AB: Oslo (2003)

  51. STIQS project-fifth report (Data on file, Sanofi Synthelabo) (2003)

  52. Lapidus, L., Borretzen, J., Fahlen, M., Thomsen, H.G., Hasselblom, S., et al.: Home treatment of deep vein thrombosis. An out-patient treatment model with once-daily injection of low-molecular-weight heparin (tinzaparin) in 555 patients. Pathophysiol. Haemost. Thromb. 32(2), 59–66 (2002)

    Article  Google Scholar 

  53. Landstingsförbundet, Kostnad per intagen patient (Cost per admitted patient). Stockholm County Council (1999)

  54. Dahl, O.E., Andreassen, G., Aspelin, T., Muller, C., Mathiesen, P., et al.: Prolonged thromboprophylaxis following hip replacement surgery—results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb. Haemost. 77(1), 26–31 (1997)

    Google Scholar 

  55. Manganelli, D., Pazzagli, M., Mazzantini, D., Punzi, G., Manca, M., et al.: Prolonged prophylaxis with unfractioned heparin is effective to reduce delayed deep vein thrombosis in total hip replacement. Respiration 65(5), 369–374 (1998)

    Article  Google Scholar 

  56. Heit, J.A., Elliott, C.G., Trowbridge, A.A., Morrey, B.F., Gent, M., et al.: Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 132(11), 853–861 (2000)

    Google Scholar 

  57. Leclerc, J.R., Gent, M., Hirsh, J., Geerts, W.H., Ginsberg, J.S.: The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. Canadian Collaborative Group. Chest 114(2 Suppl Evidence), 115S–118S (1998)

    Google Scholar 

  58. Colwell, C.W. Jr., Collis, D.K., Paulson, R., McCutchen, J.W., Bigler, G.T., et al.: Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J. Bone Joint Surg. Am. 81(7), 932–40 (1999)

    Google Scholar 

  59. Pellegrini, V.D. Jr., Clement, D., Lush-Ehmann, C., Keller, G.S., Evarts, C.M.: The John Charnley Award. Natural history of thromboembolic disease after total hip arthroplasty. Clin Orthop (333), 27–40 (1996)

  60. Hansson, P.O., Sorbo, J., Eriksson, H.: Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch. Intern. Med. 160(6), 769–74 (2000)

    Article  Google Scholar 

Download references

Acknowledgments

Acknowledgments to Sanofi Synthelabo AB, Sweden, for financial support.

Author information

Affiliations

  1. European Health Economics, Vasagatan 38, 111 20, Stockholm, Sweden

    Jonas Lundkvist

  2. Medical Management Centre, Karolinska Institutet, Stockholm, Sweden

    Jonas Lundkvist

  3. Department of Surgical Science, Akademiska Hospital, 751 85, Uppsala, Sweden

    David Bergqvist

  4. Stockholm School of Economics, Box 6501, 113 83, Stockholm, Sweden

    Bengt Jönsson

Authors
  1. Jonas Lundkvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Bergqvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bengt Jönsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonas Lundkvist.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lundkvist, J., Bergqvist, D. & Jönsson, B. Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery. Eur J Health Econ 8, 313–323 (2007). https://doi.org/10.1007/s10198-006-0017-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-006-0017-2

Keywords

  • Venous thrombosis
  • Surgery
  • Deep vein thrombosis
  • Pulmonary embolism
  • Cost-effectiveness

JEL Classification

  • 119